GTx, Inc. (GTXI) Coverage Initiated by Analysts at Robert W. Baird
Investment analysts at Robert W. Baird initiated coverage on shares of GTx, Inc. (NASDAQ:GTXI) in a report released on Tuesday, StockTargetPrices.com reports. The brokerage set an “outperform” rating and a $17.00 price target on the biopharmaceutical company’s stock. Robert W. Baird’s price target points to a potential upside of 52.88% from the stock’s current price.
Separately, Stifel Nicolaus assumed coverage on shares of GTx in a research report on Thursday, November 9th. They set a “buy” rating on the stock.
GTx (NASDAQ:GTXI) opened at $11.12 on Tuesday. GTx has a 1 year low of $2.73 and a 1 year high of $12.96.
A number of large investors have recently added to or reduced their stakes in the stock. Caxton Corp bought a new position in GTx during the third quarter worth about $531,000. Abingworth LLP bought a new position in GTx during the third quarter worth about $2,781,000. Finally, Bank of New York Mellon Corp bought a new position in GTx during the second quarter worth about $124,000. 9.02% of the stock is currently owned by institutional investors and hedge funds.
GTx Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.